Substituted benzylideneamino guanidine

ABSTRACT

1 - (2,6-DIMETHYLBENZYLIDENEAMINO)-3-HYDROXYGUANIDINE HYDROCHLORIDE; THIS COMPOUND IS USEFUL AS A HYPOTENSIVE.

United States Patent Office Patented July 13, 1971 ABSTRACT OF THE DISCLOSURE 1 (2,6 dimethylbenzylideneamino)-3-hydroxyguanidine hydrochloride; this compound is useful as a hypotensive.

This invention relates to benzylideneamino guanidine, the acid addition salts thereof, and to methods for its preparation. The substituted benzylideneamino guanidine of this invention may be represented by the following structural formula:

| NHOH CH3 The compound of Formula Ia may also be illustrated by its tautomeric equivalents such as represented by the following structural formulas:

In order to simplify this description, however, :Formula Ia \only will be used. It should be nevertheless understood that the compound of Formula lb and 1c may be represented as well as the compound of Formula Ia and the three tautorneric forms are within the concept of the present invention.

The process for preparing compound Ia may be represented as follows:

The compound of Formula Ia may be prepared by treating a dimethylbenzaldehyde S-loweralkylisothiosamicarbazone (II) with hydroxylamine (III) (the latter preferably as an acid addition salt, e.g., 'a hydrohalide such as the hydrochloride), in a solvent which dissolves both reactants, such as water in admixture with a loweralkanol, e.g., methanol or ethanol, or a tetrahydrofuran-water mixture, and the like. The reaction may be carried out at a temperature of about C. to reflux temperature, preferably at about C.-50 C. The particular solvent and temperature used is not critical in obtaining the compounds. Use of an acid addition salt of hydroxylamine (111) provides a corresponding salt of the benzylideneamino guanidine (la). The corresponding free base can be prepared from the salt in conventional manner.

The S-loweralkylisothiosemicarbazone (II) is prepared by treating a dimethylbenzaldehydethiosemicarbazone of the formula:

in solvent with methyl iodide. This reaction may be conducted in solvent such as methylene chloride, tetrahydrofuran, benzene, alcohols, e.g., lower-alkanols such as methanol, ethanol and isopropanol, mixtures thereof, and the like, from about room temperature to the reflux temperature of the system, preferably 50-80 C. Neither the particular solvent nor the reaction temperature is critical. The intermediate (11) is recovered by conventional techniques as the acid addition salt.

Said salt is converted to the free base (II) by treatment with sodium carbonate in solvent capable of dissolving the reactants such as water or a Water-lower alkanol mixture at a temperature of from about 0 to about 50 C., conveniently about room temperature. These temperatures are not, however, critical in obtaining the free base.

The compound represented by Formula Ia above is useful because it possesses pharmaceutical properties in animals. In particular, this compound is useful as a hypotensive, as indicated by its activity in the anesthetized dog and cat given .l.3 mg. of active material and tested by blood pressure measurement using a mercury manometer or transducer via a catheter inserted in the carotid or femoral artery. When so utilized, the compound may be combined with one or more pharmaceutically acceptable carriers or adjuvants. It may be administered orally or parenterally and, depending upon the compound employed and the mode of administration, the exact dosage utilized may vary.

Furthermore, the compound (Ia) may be similarly administered in the form of its non-toxic pharmaceutically acceptable acid addition salts. Such salts possess the same order of activity as the free base, are readily prepared by reacting the base with an appropriate acid and accordingly are included within the scope of the invention. Representative of such salts are the mineral 'acid salts, such as the hydrochloride, hydr-obromide, sulfate, phosphate and the like and the organic acid salts, such as the succinate, benzoate, acetate, p-toluenesulfonate, benzene-sulfonate and the like.

In general, satisfactory results are obtained when this compound is administered at a daily dosage of about .01 milligram to about 10 milligrams per kilogram of animal body weight. This daily dosage is preferably administered 2 to 4 times a day, or in sustained release form. For most large mammals such as primates, the total daily dosage is from about 0.1 milligram to about 40.0 milligrams. Dosage forms suitable for internal use comprise from about 0.25 milligram to about 20 milligrams of the active compound in intimate admixture with a solid or liquid pharmaceutically acceptable carrier or diluent.

A representative formulation suitable for oral administration is a tablet prepared by standard tabletting tech niques which contains the following:

Ingredient: Parts by weight 1 (2,6-dimethylbenzylideneamino)-3-hydroxyguanidine hydrochloride Magnesium stearate 0.5

3 4 The following example is provided for the purpose of 1 (2,6 dimethylbenzylideneamino)-3-hydroxyguanidine illustration and not by way of limitation. It is not intended hydrochloride M.P. 190192 C.

so as to limit the scope of the invention as defined in the What is claimed is: appended claims. 1. A compound of the formula EXAMPLE 5 1-(2,6-dimethylhenzylideneamino)-3-hydroxy- CH3 NH guanidine hydrochloride CH3 I NHOH NH CH3 and salts thereof with pharmaceutically acceptable acids. I NHOH 2. The compound of claim 1 which is 1-(2,6-dimethyl- CH3 benzylideneamino) -3-hydroxyguanidine hydrochloride A mixture of 2,6-dimethylbenzaldehyde l-methyliso- 15 R f rences Cited thiosemicarbazone (14.0 grns.), hydroxylamine hydro- UNITED STATES PATENTS chloride (8.7 gms.), ethanol (150 ml.) and water (15 ml.) was stirred at room temperature for 48 hours. The solu- 3377381 4/1968 Lang's et 260 564 tion was evaporated in vacuo and the residue dissolved in OTHER REFERENCES 50 ml. of 2 N hydrochloric acid, 200 ml. of water and 250 ml. of ether. The aqueous phase was separated, g g B101 and washed with 250 ml. of ether and then treated with ml. of concentrated NH OH. The resultant solid, 1-(2,6- B A HELFIN, Primary Examiner dimethylbenzylideneamino)-3-hydroxyguanidine, was 001- lected by filtration and dried and then converted to the 25 SCHWARTZ Asslstant Exammer hydrochloride salt in methanol-ether with dry hydrogen U 8 Cl XR chloride gas passed into the solution. The resultant rnixture was evaporated in vacuo to give the title product 424-326; 260552 

